Advertisement

Neurological Sciences

, Volume 40, Issue 1, pp 217–220 | Cite as

Efficacy of subcutaneous immunoglobulin therapy in a patient with autoimmune encephalitis: a case report

  • Angela Teresa LazzaroEmail author
  • Leonardo Romeo
  • Camillo Gnessi
Letter to the Editor
  • 111 Downloads

Dear Editor,

Encephalitis is defined as inflammation of the brain parenchyma associated with neurological dysfunction [1]. Limbic encephalitis (LE) is characterized by rapid development of confusional episodes, memory deficits, mood changes, and epileptic seizures.

While paraneoplastic LE generally has a poor prognosis, autoimmune LE often responds well to immunotherapy [2]. In case series, but not controlled studies, patients with autoimmune encephalitis have been shown to benefit from first-line immunotherapies that include corticosteroids, intravenous immunoglobulins (IVIG) therapy, and plasma exchange, either alone or in combination [3].

In this paper, we report on the efficacy of 20%-concentrated subcutaneous immunoglobulin G (SCIG, Hizentra®, CSL Behring AG) in a patient with autoimmune encephalitis, treated initially and successfully with IVIG. To our knowledge, this is the first clinical case with SCIG showing a maintenance of the outcomes with IVIG. In December 2016, a...

Notes

Acknowledgements

Publishing support and journal styling services were provided by SEEd Medical Publishers, and funded by CSL Behring, Italy.

Compliance with ethical standards

Informed consent

Informed consent was obtained from the patient described in this report.

Conflict of interest

Author A has received financial support for attending symposia from AB Pharm, Ihms Health, Sanofi Genzyme, CSL Behring. Author B and author C declare that they have no conflict of interest.

References

  1. 1.
    Venkatesan A, Geocadin RG (2014) Diagnosis and management of acute encephalitis: a practical approach. Neurol Clin Pract 4:206–215.  https://doi.org/10.1212/CPJ.0000000000000036 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Derry CP, Wilkie MD, Al-Shahi Salman R, Davenport RJ (2011) Autoimmune limbic encephalitis. Clin Med (Lond) 11:476–478.  https://doi.org/10.7861/clinmedicine.11-5-476 CrossRefGoogle Scholar
  3. 3.
    Lünemann JD, Quast I, Dalakas MC (2016) Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics 13:34–46.  https://doi.org/10.1007/s13311-015-0391-5 CrossRefPubMedGoogle Scholar
  4. 4.
    Harutyunyan G, Hauer L, Dünser MW, Karamyan A, Moser T, Pikija S, Leitinger M, Novak HF, Trinka E, Sellner J (2017) Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival. Neurocrit Care 27:82–89.  https://doi.org/10.1007/s12028-016-0370-7 CrossRefPubMedGoogle Scholar
  5. 5.
    Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404.  https://doi.org/10.1016/S1474-4422(15)00401-9 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyS. Maria Goretti HospitalLatinaItaly
  2. 2.Department of University DiabetologyS. Maria Goretti HospitalLatinaItaly

Personalised recommendations